US 12,390,525 B2
Constructs for enhancing immune responses
Hildegund C. J. Ertl, Villanova, PA (US); Marcio O. Lasaro, Maple Shade, NJ (US); and Luis C. S. Ferreira, Sao Paulo (BR)
Assigned to THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, Philadelphia, PA (US)
Filed by THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, Philadelphia, PA (US)
Filed on Nov. 18, 2021, as Appl. No. 17/529,665.
Application 17/529,665 is a continuation of application No. 16/408,730, filed on May 10, 2019, granted, now 11,207,402.
Application 16/408,730 is a continuation of application No. 15/639,296, filed on Jun. 30, 2017, granted, now 10,328,146, issued on Jun. 25, 2019.
Application 15/639,296 is a continuation of application No. 14/628,784, filed on Feb. 23, 2015, granted, now 9,724,406, issued on Aug. 8, 2017.
Application 14/628,784 is a continuation of application No. 13/239,771, filed on Sep. 22, 2011, granted, now 8,962,816, issued on Feb. 24, 2015.
Application 13/239,771 is a continuation of application No. 12/438,889, abandoned, previously published as PCT/US2007/018939, filed on Aug. 28, 2007.
Claims priority of provisional application 60/840,526, filed on Aug. 28, 2006.
Prior Publication US 2022/0331423 A1, Oct. 20, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/245 (2006.01); A61K 39/12 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/245 (2013.01) [A61K 39/12 (2013.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); A61K 2039/53 (2013.01); A61K 2039/57 (2013.01); C07K 2319/00 (2013.01); C07K 2319/10 (2013.01); C12N 2710/10043 (2013.01); C12N 2710/16622 (2013.01); C12N 2710/16634 (2013.01); Y02A 50/30 (2018.01)] 23 Claims
 
1. A method of inducing an immune response comprising providing to a subject in need thereof a vaccine comprising a nucleic acid molecule which encodes a fusion protein, wherein the fusion protein comprises:
a. a first polypeptide segment comprising at least amino acids 1-240 of a mature Herpes simplex virus (HSV) glycoprotein D, wherein the first polypeptide segment does not comprise a full length mature glycoprotein D;
b. a second polypeptide segment comprising at least one antigen, wherein the at least one antigen is not an HSV glycoprotein D antigen, wherein the N terminus of the second polypeptide segment is linked to the C terminus of the first polypeptide segment; and
c. a third polypeptide segment comprising a C terminal portion of the HSV glycoprotein D, wherein the N terminus of the third polypeptide segment is linked to the C terminus of the second polypeptide segment,
wherein the at least one antigen is selected from the group consisting of: an influenza virus antigen; a nucleoprotein P influenza virus antigen, a Plasmodium antigen, a human papilloma virus (HPV) antigen, a human papilloma virus HPV16 antigen, an HPV E5 protein, an HPV E6 protein, an HPV E7 protein, a human immunodeficiency virus (HIV) antigen, and an HIV gag antigen.